Optimizing antibiotics policy in the Netherlands. IV. Guidelines for empirical antimicrobial therapy in hospitals of sepsis in adults;Optimaliseren van her antibioticabeleid in Nederland. IV. Swab- richtlijnen voor antimicrobiele therapie in bet ziekenhuis bij volwassenen met sepsis

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 12, 1999, Pages 611-617

  Van Kasteren, M E E ^a   Stobberingh, E E ^b   Janknegt, R ^c   Wijnands, W J A ^d   Van Der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d DEVENTER HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; HEALTH CARE POLICY; HOSPITAL CARE; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; SEPSIS; CROSS INFECTION; FEMALE; LAW; MALE; MEDICAL LITERATURE; NEUTROPENIA; STANDARD;

ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; LEGISLATION, HOSPITAL; MALE; NETHERLANDS; NEUTROPENIA; PHARMACOPOEIAS; SEPSIS;

EID: 0033586379     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kasteren MEE van, Wijnands WJA, Stobberingh E, Janknegt R, Verbrugh HA, Meer JWM van der. Optimaliseren van het antibioticabeleid in Nederland. I. De Stichting Werkgroep Antibioticabeleid (SWAB). Ned Tijdschr Geneeskd 1998;142:949-51.
2. Jong R de, Fleer A, Groot R de, Janknegt R, Kimpen JLL, Rademaker CMA, et al., redacteuren. Blauwdruk pediatrische anti-microbicle therapie. 's-Hertogenbosch: Glaxo Wellcome: 1995.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and the guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992;6:1645-55.
4. Verbist I. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. International Study Group. Scand J Infect Dis 1993:91 Suppl:14-24.
5. Young LS. Therapy of sepsis. Clin Microbiol Infect 1997:3 Suppl 4:61-5.
6. Cunha BA. Antibiotic treatment of sepsis. Med Clin North Am 1995;79:551-8.
7. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990;89:137-41.
8. Capdevila JA, Segarra A, Planes AM, Ramirez-Arellallo M, Pahissa A, Piera L, et al. Successfull treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993;8:231-4.
9. Nguyen MH, Peacock Jr JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
10. Extermann M, Regamey C. Empirical antibiotic treatment of sepsis in non-neutropenic patients: single agent or combination therapy? Infection 1994;1:5-7.
11. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-13.
12. Korvick JA, Bryan CS, Farber B, Beam TR, Schenfeld L, Weinbaum D, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36:2639-44.
13. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-amino-glycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
14. Shah PM. The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia. J Chemother 1996:8(Suppl 2):105-11.
15. Bryson HM, Brogden RN. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
16. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115: 585-90.
17. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamiein in patients with serious infections. Lancet 1993:341:335-9.
18. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
19. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993:17(Suppl 2):S378-84.
20. Pauw BE de, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP, Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994;120:834-44.
21. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
22. Cometta A, Calandra T, Gaya H, Zinner SH, Bock R de, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-15.
23. Hess U, Bohme C, Rev K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998;6:402-9.
24. Pauw BE de, Donnelly JP. Controversies in the antibacterial treatment of patients with neutropenia. Cancer Invest 1997;15:37-46.
25. EORTC & National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
26. Ramphal R. Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992;36:1062-7.